<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126343</url>
  </required_header>
  <id_info>
    <org_study_id>UP0050</org_study_id>
    <secondary_id>2019-002797-31</secondary_id>
    <nct_id>NCT04126343</nct_id>
  </id_info>
  <brief_title>A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants</brief_title>
  <official_title>A Single-Center, Randomized, Placebo-Controlled, 3 Treatment Period Crossover Study to Assess the Effect of Padsevonil on Cardiac Repolarization (QTc Interval) (Using Moxifloxacin as a Positive Control) in Healthy Study Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effects on cardiac repolarization of high-dose&#xD;
      padsevonil (PSL) in comparison to placebo in healthy study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on available data, UCB has decided to stop development of padsevonil as adjunctive&#xD;
    treatment of focal-onset seizures&#xD;
  </why_stopped>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected Change From Baseline in QTcF on Day 8 for Padsevonil</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the padsevonil and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline in QTcF After a Single Dose of Moxifloxacin on Day 8</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 1</measure>
    <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 8</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline for PR Interval on Day 1</measure>
    <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline for PR Interval on Day 8</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline for QRS Interval on Day 1</measure>
    <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected Change From Baseline for QRS Interval on Day 8</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
    <description>Number of Participants with treatment-emergent changes of electrocardiogram waveforms as T-waves and U-waves. If a given morphology occurs multiple times at a given time point, that occurrence was only counted 1 time for that time point. If more than 1 morphology type was observed at a given time point, both morphology types were counted. A subject can appear in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Padsevonil</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for padsevonil, using an analysis of variance (ANOVA) mixed-effect model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Metabolite 1</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 1, using an analysis of variance (ANOVA) mixed-effect model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTcF Evaluated at Drug-Specific Tmax for Metabolite 2</measure>
    <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 2, using an analysis of variance (ANOVA) mixed-effect model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) for Padsevonil</measure>
    <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>Cmax,ss: Maximum observed plasma concentration of padsevonil at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Observed Maximum Concentration (Tmax) at Steady State for Padsevonil</measure>
    <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>tmax: Time of observed maximum plasma concentration at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve (AUCtau) at Steady State for Padsevonil</measure>
    <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
    <description>AUCtau: Area under the plasma concentration time curve over a dosing interval at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events From Baseline to Safety Follow-up (up to Day 67)</measure>
    <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events From Baseline to Safety Follow-up (up to Day 67)</measure>
    <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
    <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Related Adverse Events From Baseline to Safety Follow-up (up to Day 67)</measure>
    <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events Leading to Discontinuation of the Study From Baseline to Safety Follow-up (up to Day 67)</measure>
    <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. The results of this Primary Outcome Measure are summarized from the Adverse Event pages of the Case Report Forms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Study Participants</condition>
  <arm_group>
    <arm_group_label>Padsevonil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet&#xD;
Route of administration: Oral use&#xD;
Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period</description>
    <arm_group_label>Padsevonil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet&#xD;
Route of administration: Oral use&#xD;
Study participants will receive moxifloxacin once during the Treatment Period</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet&#xD;
Route of administration: Oral use&#xD;
Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_label>Padsevonil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             informed consent form (ICF)&#xD;
&#xD;
          -  Participant who is overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring&#xD;
&#xD;
          -  Body weight of at least 50 kilogram (kg) (males) or 45 kg (females) and body mass&#xD;
             index (BMI) within the range 18 to 30 kg/m2 (inclusive)&#xD;
&#xD;
          -  Male and/or female:&#xD;
&#xD;
        A male study participant must agree to use contraception during the Treatment Period and&#xD;
        for at least 90 days after the last dose of study medication and refrain from donating&#xD;
        sperm during this period&#xD;
&#xD;
        A female participant is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
        and at least one of the following conditions applies:&#xD;
&#xD;
        Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the&#xD;
        contraceptive guidance during the Treatment Period and for at least 90 days after the last&#xD;
        dose of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any components of the study medication or&#xD;
             comparative drugs as stated in this protocol or history of tendon pathology secondary&#xD;
             to use of quinolone antibiotics&#xD;
&#xD;
          -  Participant has a history of unexplained syncope or a family history of sudden death&#xD;
             due to long QT syndrome&#xD;
&#xD;
          -  Participant has a present condition of respiratory or cardiovascular disorders, eg,&#xD;
             cardiac insufficiency, coronary heart disease, hypertension, arrhythmia,&#xD;
             tachyarrhythmia, or myocardial infarction&#xD;
&#xD;
          -  Past or intended use of over-the-counter (OTC) or prescription medication including&#xD;
             herbal medications within 2 weeks or 5 half-lives prior to dosing.&#xD;
&#xD;
          -  Participant has used hepatic enzyme-inducing drugs (eg, glucocorticoids,&#xD;
             phenobarbital, isoniazid, phenytoin, rifampicin, etc) within 2 months prior to the&#xD;
             first dose of study medication&#xD;
&#xD;
          -  Participant has previously received padsevonil (PSL) in this or any other study&#xD;
&#xD;
          -  Participant has any clinically relevant electrocardiogram (ECG) finding at the&#xD;
             Screening Visit or at Baseline. Participant has an abnormality in the 12-lead ECG&#xD;
             that, in the opinion of the Investigator, increases the risks associated with&#xD;
             participating in the study. In addition, any participant with any of the following&#xD;
             findings will be excluded:&#xD;
&#xD;
               1. QT interval corrected for heart rate using the Fridericia method (QTcF) ≥450 ms&#xD;
                  (on mean of triplicate ECG recordings);&#xD;
&#xD;
               2. Other conduction abnormalities (defined as PR interval &gt;220 ms);&#xD;
&#xD;
               3. QRS interval &gt;109 ms;&#xD;
&#xD;
               4. Any rhythm other than sinus rhythm;&#xD;
&#xD;
               5. Any history of Wolff-Parkinson-White Syndrome, Brugada Syndrome, unexplained&#xD;
                  syncope, or ventricular tachycardia;&#xD;
&#xD;
               6. Family history of QTc prolongation or of unexplainable sudden death at &lt;50 years&#xD;
                  of age&#xD;
&#xD;
          -  Participant has made a blood or plasma donation or has had a comparable blood loss&#xD;
             (&gt;450 mL) within 30 days prior to the Screening Visit. Blood donation during the study&#xD;
             is not permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0050 001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <results_first_submitted>May 21, 2021</results_first_submitted>
  <results_first_submitted_qc>May 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy study participants</keyword>
  <keyword>Padsevonil</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Cardiac repolarization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT04126343/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT04126343/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll study participants in October 2019 and concluded in May 2020.</recruitment_details>
      <pre_assignment_details>The Participant Flow refers to the Safety Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence: ABC</title>
          <description>Padsevonil (PSL) Treatment Period (Treatment A)- participants received PSL 100 milligrams (mg) to 400 mg, orally twice daily (bid) during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon.&#xD;
Placebo Treatment Period (Treatment B)-participants received Placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
Moxifloxacin (MXF) Treatment Period (Treatment C)- participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon.&#xD;
Participants received PSL, Placebo, and MXF treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence: ACB</title>
          <description>Participants received PSL, MXF, and Placebo treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence: BAC</title>
          <description>Participants received Placebo, PSL, and MXF treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence: BCA</title>
          <description>Participants received Placebo, MXF, and PSL treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence: CAB</title>
          <description>Participants received MXF, PSL, and Placebo treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence: CBA</title>
          <description>Participants received MXF, Placebo, and PSL treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Padsevonil Period</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Placebo Period</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Moxifloxacin Period</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Related to COVID-19 pandemic</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Safety Set which consisted of all study participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Sequence: ABC</title>
          <description>Padsevonil (PSL) Treatment Period (Treatment A) participants received PSL 100 milligrams (mg) to 400 mg, orally twice daily (bid) during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon.&#xD;
Placebo Treatment Period (Treatment B) participants received Placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
Moxifloxacin (MXF) Treatment Period (Treatment C) participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon.&#xD;
Participants received PSL, Placebo, and MXF treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Sequence: ACB</title>
          <description>Participants received PSL, MXF, and Placebo treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B3">
          <title>Treatment Sequence: BAC</title>
          <description>Participants received Placebo, PSL, and MXF treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B4">
          <title>Treatment Sequence: BCA</title>
          <description>Participants received Placebo, MXF, and PSL treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B5">
          <title>Treatment Sequence: CAB</title>
          <description>Participants received MXF, PSL, and Placebo treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B6">
          <title>Treatment Sequence: CBA</title>
          <description>Participants received MXF, Placebo, and PSL treatments at the first, the second and the third treatment periods respectively, with a minimum 7-day washout period between each treatment periods.</description>
        </group>
        <group group_id="B7">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="6.9"/>
                    <measurement group_id="B2" value="30.2" spread="9.5"/>
                    <measurement group_id="B3" value="38.4" spread="7.1"/>
                    <measurement group_id="B4" value="37.0" spread="7.6"/>
                    <measurement group_id="B5" value="36.8" spread="9.9"/>
                    <measurement group_id="B6" value="32.4" spread="5.6"/>
                    <measurement group_id="B7" value="35.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Placebo-corrected Change From Baseline in QTcF on Day 8 for Padsevonil</title>
        <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the padsevonil and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline in QTcF on Day 8 for Padsevonil</title>
          <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the padsevonil and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>milliseconds (ms)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-4.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-4.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-3.5" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3.6" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-3.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-4.6" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-4.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-4.7" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-6.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-4.6" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-3.8" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-5.3" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-7.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-8.1" upper_limit="-1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-4.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline in QTcF After a Single Dose of Moxifloxacin on Day 8</title>
        <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline in QTcF After a Single Dose of Moxifloxacin on Day 8</title>
          <description>Placebo-corrected change from Baseline in corrected QT interval (QTc), based on Fridericia's correction (QTcF) method (ΔΔQTcF) evaluated during the Target Dose Day of the moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-1.2" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-0.2" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0.5" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-0.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="6.2" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="7.3" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="8.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.8" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.4" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.3" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="6.2" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.3" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="5.3" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="3.8" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 1</title>
        <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 1</title>
          <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.6" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-1.7" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1.6" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" lower_limit="-4.2" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.9" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-0.9" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.7" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-2.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 8</title>
        <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline in Heart Rate (HR) Interval on Day 8</title>
          <description>Placebo-corrected change from Baseline in HR, (ΔΔHR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: 0.75 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.7" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-1.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.6" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.4" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.9" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-1.3" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.8" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-1.6" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3.7" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.5" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-3.5" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.7" upper_limit="0.5"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-0.1" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-4.6" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.3" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-4.4" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-3.5" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-3.3" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-2.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.2" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-5.1" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.4" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 18 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-0.6" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.2" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.3" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline for PR Interval on Day 1</title>
        <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline for PR Interval on Day 1</title>
          <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1.2" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.2" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-0.2" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-0.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-0.2" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="-0.7" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0.9" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-1.8" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-0.8" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline for PR Interval on Day 8</title>
        <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline for PR Interval on Day 8</title>
          <description>Placebo-corrected change from Baseline in PR, (ΔΔPR) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: 0.75 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-0.4" upper_limit="5.2"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-3.5" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="-0.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-3.7" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-1.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-4.1" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-0.4" upper_limit="5.2"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-3.1" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0.2" upper_limit="6.0"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-4.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.1" upper_limit="6.6"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-3.3" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.4" upper_limit="7.0"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-3.3" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-3.7" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-6.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="1.1" upper_limit="7.2"/>
                    <measurement group_id="O2" value="-3.3" lower_limit="-6.2" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.5" upper_limit="6.2"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-4.9" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-0.5" upper_limit="5.7"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-4.8" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-2.0" upper_limit="5.3"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-6.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 18 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-3.7" upper_limit="3.2"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-5.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.1" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-4.8" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline for QRS Interval on Day 1</title>
        <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 1 : 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline for QRS Interval on Day 1</title>
          <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment. The Target Dose for moxifloxacin was at Day 8. Therefore, the data was analyzed at Day 8 only.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.5" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.6" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.7" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.7" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.6" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.7" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.6" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.6" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placebo-corrected Change From Baseline for QRS Interval on Day 8</title>
        <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Placebo-corrected Change From Baseline for QRS Interval on Day 8</title>
          <description>Placebo-corrected change from Baseline for QRS interval, (ΔΔQRS) evaluated during the Target Dose Day of the padsevonil/moxifloxacin and placebo Treatment Periods, using linear mixed-effects model analysis.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8: 0.75 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.9" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.7" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.9" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.7" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.8" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.5" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.25 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 0.5 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.9" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1 hour Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.8" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 1.5 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-1.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 2 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.7" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 3 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.9" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.5" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 4 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.1" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.7" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 6 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.8" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 8 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.8" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.7" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 12 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-0.4" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 18 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.0" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-1.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8: 24 hours Postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.7" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</title>
        <description>Number of Participants with treatment-emergent changes of electrocardiogram waveforms as T-waves and U-waves. If a given morphology occurs multiple times at a given time point, that occurrence was only counted 1 time for that time point. If more than 1 morphology type was observed at a given time point, both morphology types were counted. A subject can appear in more than 1 category.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11.&#xD;
On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (QT/QTc Set)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</title>
          <description>Number of Participants with treatment-emergent changes of electrocardiogram waveforms as T-waves and U-waves. If a given morphology occurs multiple times at a given time point, that occurrence was only counted 1 time for that time point. If more than 1 morphology type was observed at a given time point, both morphology types were counted. A subject can appear in more than 1 category.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biphasic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U-Wave Presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Padsevonil</title>
        <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for padsevonil, using an analysis of variance (ANOVA) mixed-effect model.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (QT/QTc Set)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/corrected QT interval (QTc) Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Padsevonil</title>
          <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for padsevonil, using an analysis of variance (ANOVA) mixed-effect model.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.7" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Metabolite 1</title>
        <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 1, using an analysis of variance (ANOVA) mixed-effect model.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Metabolite 1 (QT/QTc Set)</title>
            <description>Participants received PSL (padsevonil metabolite 1) 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF Evaluated at Drug-specific Tmax for Metabolite 1</title>
          <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 1, using an analysis of variance (ANOVA) mixed-effect model.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-2.3" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTcF Evaluated at Drug-Specific Tmax for Metabolite 2</title>
        <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 2, using an analysis of variance (ANOVA) mixed-effect model.</description>
        <time_frame>Day 8 : 0.75, 0.5, 0.25 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
        <group_list>
          <group group_id="O1">
            <title>Metabolite 2 (QT/QTc Set)</title>
            <description>Participants received PSL (padsevonil metabolite 2) 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed the QT/QTc Set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF Evaluated at Drug-Specific Tmax for Metabolite 2</title>
          <description>Change from Baseline in QTcF (ΔQTcF) evaluated at drug-specific tmax (Δtmax) for metabolite 2, using an analysis of variance (ANOVA) mixed-effect model.</description>
          <population>The QT/QTc Set included all study participants in the SS with measurements at Baseline as well as on-treatment with at least 1 postdose time point with a valid change-from Baseline QTcF (ΔQTcF) value.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) for Padsevonil</title>
        <description>Cmax,ss: Maximum observed plasma concentration of padsevonil at steady state.</description>
        <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (PKS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period.&#xD;
On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Pharmacokinetic Set (PKS).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady State (Cmax, ss) for Padsevonil</title>
          <description>Cmax,ss: Maximum observed plasma concentration of padsevonil at steady state.</description>
          <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>nanogram per milliliter (ng/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2119" lower_limit="1912" upper_limit="2348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Observed Maximum Concentration (Tmax) at Steady State for Padsevonil</title>
        <description>tmax: Time of observed maximum plasma concentration at steady state.</description>
        <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (PKS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period.&#xD;
On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Pharmacokinetic Set (PKS).</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Observed Maximum Concentration (Tmax) at Steady State for Padsevonil</title>
          <description>tmax: Time of observed maximum plasma concentration at steady state.</description>
          <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5100" lower_limit="0.250" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Time Curve (AUCtau) at Steady State for Padsevonil</title>
        <description>AUCtau: Area under the plasma concentration time curve over a dosing interval at steady state.</description>
        <time_frame>Day 8: 0.5 hours predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 hours postdose</time_frame>
        <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (PKS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period.&#xD;
On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Pharmacokinetic Set (PKS).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve (AUCtau) at Steady State for Padsevonil</title>
          <description>AUCtau: Area under the plasma concentration time curve over a dosing interval at steady state.</description>
          <population>The PKS included all study participants who received at least 1 dose of study medication, had no important Protocol deviations affecting the PK, and for whom at least 1 measurable PK concentration was available. Here, number of participants were included who were evaluable for the assessment.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8586" lower_limit="7752" upper_limit="9510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
        <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
        <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (SS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
          <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
          <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
        <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
        <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (SS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
          <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
          <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Related Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (SS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Related Adverse Events From Baseline to Safety Follow-up (up to Day 67)</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events Leading to Discontinuation of the Study From Baseline to Safety Follow-up (up to Day 67)</title>
        <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. The results of this Primary Outcome Measure are summarized from the Adverse Event pages of the Case Report Forms.</description>
        <time_frame>From Baseline to Safety Follow-up (up to Day 67)</time_frame>
        <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Padsevonil (SS)</title>
            <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (SS)</title>
            <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events Leading to Discontinuation of the Study From Baseline to Safety Follow-up (up to Day 67)</title>
          <description>An Adverse Event is any untoward medical occurrence in a subject or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage. The results of this Primary Outcome Measure are summarized from the Adverse Event pages of the Case Report Forms.</description>
          <population>Safety Set included all participants who received at least 1 dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to Safety Follow Up (up to Day 67)</time_frame>
      <desc>Any AE that starts on or after the date of the first dose of study drug and on or before the last date of the last treatment period or any unresolved event already present before administration of treatment that worsens in intensity following exposure to the treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Padsevonil (SS)</title>
          <description>Participants received PSL 100 mg to 400 mg orally bid during the 11 Days PSL Treatment Period. On Day 8, the Target Dose Day, participants received PSL 400 mg in the morning only and placebo in the afternoon. Participants formed Safety Set (SS).</description>
        </group>
        <group group_id="E2">
          <title>Moxifloxacin (SS)</title>
          <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. On Day 8, the Target Dose Day, participants received MXF 400 mg in the morning and placebo in the afternoon. Participants formed the SS.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (SS)</title>
          <description>Participants received placebo matched to PSL Treatment Period doses, bid up to Day 11. Participants formed the SS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

